A recent study showed that the competitive GCase inhibitor chaperone Ambroxol reduced intracellular Tau and α-synucleinin in cholinergic neurons carrying the GBA1WT/N370S genotype derived from a donor with Parkinson’s disease. The gene discussed is MAPT; the disease is Parkinson disease.